Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00289_DB00907_nanopub.RAzzl-rbEd4VNOgNd9AeGyCfqqM-ReXprOJeBrhNA4I04#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00289_DB00907 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00289_DB00907 label "DDI between Atomoxetine and Cocaine - CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor. [drugbank_resource:DB00289_DB00907]" assertion.
- drugbank_resource:DB00289_DB00907 identifier "drugbank_resource:DB00289_DB00907" assertion.
- drugbank_resource:DB00289_DB00907 title "DDI between Atomoxetine and Cocaine - CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor." assertion.
- drugbank:DB00907 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00289_DB00907 assertion.
- drugbank:DB00289 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00289_DB00907 assertion.